As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...
H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved ...
This new technique for studying cell receptors could have sweeping implications for drug development
Researchers created a tool capable of comprehensively mapping crucial interactions underlying drug efficacy in one superfamily of cell receptors. One in every three FDA-approved drugs targets a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results